A clone report from blood at every treatment cycle
Blood tests can already detect tumour DNA. Reporting which sub-populations of the tumour are growing or shrinking, cycle by cycle, would turn the test into an evolution monitor.
Phylogenetic ctDNA analysis, as developed in TRACERx, assigns plasma variants to tumour subclones and tracks their relative abundance. The proposal is a standardised clinical report in which each ctDNA draw lists clone fractions, emergent clones, and clone-specific drug sensitivities, rather than a flat list of variants and allele frequencies.
- Tumour heterogeneity and clonal evolution · A tumour is many tumours. Treatments that kill most cells leave the rest to grow back, changed.
- Acquired resistance to every therapy · Nearly every targeted therapy stops working within months to a few years as the tumour adapts.
Pages like this
not linked directly; found by shared links- IdeactDNA-guided dose holidays for lung cancer targeted therapy
Shares Osimertinib, Tumour heterogeneity and clonal evolution, Circulating tumour DNA (ctDNA), Acquired resistance to every therapy.
- IdeaAdd a drug when the blood test turns, without stopping the one that works
Shares Molecular-progression switching beyond ESR1, Osimertinib, Acquired resistance to every therapy, Liquid biopsy (ctDNA).
- IdeaPause a failed drug so the tumour becomes sensitive to it again
Shares Osimertinib, Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy, Liquid biopsy (ctDNA).
- IdeaLook for the resistant sub-population before the first dose
Shares Variant allele frequency (VAF), Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy, Liquid biopsy (ctDNA).
- IdeaSlow the tumour's mutation engine with APOBEC inhibitors during targeted therapy
Shares Osimertinib, Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy, Non-small-cell lung cancer.
- IdeaAutonomous closed-loop adaptive therapy driven by blood tests and evolutionary models
Shares Osimertinib, Circulating tumour DNA (ctDNA), Acquired resistance to every therapy, Liquid biopsy (ctDNA).
- Key paperTRACERx first 100: tracking how lung cancers evolve, and how chromosomal chaos predicts relapse
Shares Gerlinger: a single biopsy misses most of the mutations in a kidney tumour, Tumour heterogeneity and clonal evolution, Circulating tumour DNA (ctDNA), Acquired resistance to every therapy.
- IdeaForecast the next resistance mutation like the weather
Shares Osimertinib, Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy, Liquid biopsy (ctDNA).